Eighty-five percent of all incoming CEOs in 2024 stepped into their role for the first time, according to Russell Reynolds Associates’ “The Transformation of the CEO: Global CEO Turnover Index Annual Report.”
The report, which tracked CEO exits at companies listed on 13 indices, including the S&P 500, found that “serial CEOs” — who exit one organization for another top role elsewhere — have become less common. The shift was attributed to increased scrutiny and pressure in the role, along with a wave of retirements and planned successions. Among CEO departures in 2024, 22% were part of a planned succession process.
As companies sour on the serial CEO, boards of directors seem to be finding new leadership among those who haven’t yet helmed a business, but have had C-suite experience.
Becker’s has reported on several healthcare CEO first-timers, such as Sarah Ness, who will become next president and CEO of Vancouver, Wash.-based Peacehealth on Jan. 3. She currently serves as executive vice president and chief administrative officer, and previously held leadership roles in marketing and communications, according to her LinkedIn profile.
Additionally, Eduardo Conrado, president of St. Louis-based Ascension, will succeed CEO Joseph Impicciche on Jan. 1. Mr. Conrado previously held C-suite roles in strategy, innovation and marketing.
